<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Xanthine-oxidase inhibitor; Uricosuric drugs; Hyperuricaemia: gout; Allopurinol; Febuxostat; Sulfinpyrazone; Probenecid; Benzbromarone" /><meta name="IX" content="Xanthine-oxidase inhibitor; Uricosuric drugs; Hyperuricaemia: gout; Allopurinol; Febuxostat; Sulfinpyrazone; Probenecid; Benzbromarone" /><title>Long-term control of gout: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="5314.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="5314.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=5314.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5310.htm">10.1.4 Gout and cytotoxic-induced hyperuricaemia</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="5312.htm" title="Previous: COLCHICINE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="5315.htm" title="Next: ALLOPURINOL">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_5314">Long-term control of gout</h1><?highlighter on?><div id="pC" class="jN"><div><div id="_5314.1"><p>Frequent recurrence of acute attacks of gout, the presence of tophi,
or signs of chronic gouty arthritis may call for the initiation of
long-term (‘interval’) treatment. For long-term control of gout the
formation of uric acid from purines may be reduced with the xanthine-oxidase
inhibitors <span>allopurinol</span> or febuxostat; alternatively
the uricosuric
drug <span>sulfinpyrazone</span> may be used to increase the
excretion of uric acid in the urine. Treatment should be continued
indefinitely to prevent further attacks of gout by correcting the hyperuricaemia. These
drugs should never be started during an acute attack; they are usually started 1–2 weeks after the attack has settled.
The initiation of treatment may precipitate an acute attack, and therefore
an anti-inflammatory analgesic or <span>colchicine</span> should
be used as a prophylactic and continued for at least one month after
the hyperuricaemia has been corrected. However, if an acute attack
develops during treatment, then the treatment should continue at the
same dosage and the acute attack treated in its own right.</p></div><p><b><span>Allopurinol</span></b> is widely used and
is especially useful in patients with renal impairment or urate stones
when uricosuric drugs cannot be used; <span id="_5314.2">it is <i>not</i> indicated for
the treatment of asymptomatic hyperuricaemia</span>. It can cause rashes. </p><p><b>Febuxostat</b> is licensed for the treatment of chronic hyperuricaemia where urate
deposition has already occurred; it is <i>not</i> indicated
for patients in whom the rate of urate formation is greatly increased,
such as in malignant disease or in Lesch-Nyhan syndrome.</p><div id="_207451"><div class="cN"><h2 class="cBR">NICE guidance<sup class="footnote"><a title="Go to footnote" href="5314.htm#footnote213613">(1)</a></sup></h2><h3 class="cBP">Febuxostat for the management of hyperuricaemia in
patients with gout (December 2008)</h3><p>Febuxostat is recommended as an option for the management of
chronic hyperuricaemia in gout only for patients who are intolerant
of allopurinol or for whom allopurinol is contra-indicated.</p><p>For the purposes of this guidance, intolerance of allopurinol
is defined as adverse effects that are sufficiently severe to warrant
discontinuation, or to prevent full dose escalation for optimal effectiveness.</p></div></div><p><b><span>Sulfinpyrazone</span></b> can be used instead
of <span>allopurinol</span>, or in conjunction with it in cases
that are resistant to treatment. </p><p><b><span>Probenecid</span></b> (available from <a title="appendix: Special-order Manufacturers" href="106216.htm#_106216">‘special-order’ manufacturers or specialist importing
companies</a>) is a uricosuric drug used
to prevent nephrotoxicity associated with cidofovir (<a title="monograph: CIDOFOVIR" href="64326.htm#_64326">section 5.3.2.2</a>).</p><p><b>Benzbromarone</b> (available from <a title="appendix: Special-order Manufacturers" href="106216.htm#_106216">‘special-order’ manufacturers or specialist importing
companies</a>) is a uricosuric drug that
can be used in patients with mild renal impairment.</p><p><span id="_5314.3">Crystallisation of urate in the urine can occur with the uricosuric
drugs and it is important to ensure an adequate urine output especially
in the first few weeks of treatment. </span>As an additional
precaution the urine may be rendered alkaline.</p><p><span>Aspirin</span> and other <span>salicylates</span> antagonise the uricosuric drugs; they do not antagonise <span>allopurinol</span> but are nevertheless <i>not</i> indicated
in gout.</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_5315"><a href="5315.htm" title="ALLOPURINOL">ALLOPURINOL</a></li><li id="_204954"><a href="204954.htm" title="FEBUXOSTAT">FEBUXOSTAT</a></li><li id="_5318"><a href="5318.htm" title="PROBENECID">PROBENECID</a></li><li id="_5320"><a href="5320.htm" title="SULFINPYRAZONE">SULFINPYRAZONE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="5312.htm">Previous: COLCHICINE</a> | <a class="top" href="5314.htm#">Top</a> | <a accesskey="]" href="5315.htm">Next: ALLOPURINOL</a> ►</div><div class="cF"><div class="footnote" id="footnote213613"><sup>(1)</sup>The <i>Scottish Medicines Consortium</i> issued similar
advice in August 2010</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>